Vertex Pharmaceuticals (1VRTX) Stock Overview
Operates as a biotechnology company in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1VRTX from our risk checks.
1VRTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$385.25 |
| 52 Week High | US$449.50 |
| 52 Week Low | US$316.00 |
| Beta | 0.32 |
| 1 Month Change | -7.61% |
| 3 Month Change | -0.73% |
| 1 Year Change | -14.94% |
| 3 Year Change | 32.66% |
| 5 Year Change | 111.65% |
| Change since IPO | 95.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1VRTX | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -0.7% | 1.3% | 1.8% |
| 1Y | -14.9% | 19.8% | 13.8% |
Return vs Industry: 1VRTX underperformed the Italian Biotechs industry which returned 19.8% over the past year.
Return vs Market: 1VRTX underperformed the Italian Market which returned 13.8% over the past year.
Price Volatility
| 1VRTX volatility | |
|---|---|
| 1VRTX Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in IT Market | 7.7% |
| 10% least volatile stocks in IT Market | 3.0% |
Stable Share Price: 1VRTX has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1VRTX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 6,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
| 1VRTX fundamental statistics | |
|---|---|
| Market cap | €97.40b |
| Earnings (TTM) | €3.42b |
| Revenue (TTM) | €10.38b |
Is 1VRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1VRTX income statement (TTM) | |
|---|---|
| Revenue | US$12.00b |
| Cost of Revenue | US$5.56b |
| Gross Profit | US$6.44b |
| Other Expenses | US$2.49b |
| Earnings | US$3.95b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.56 |
| Gross Margin | 53.67% |
| Net Profit Margin | 32.94% |
| Debt/Equity Ratio | 0% |
How did 1VRTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/31 02:35 |
| End of Day Share Price | 2026/03/31 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vertex Pharmaceuticals Incorporated is covered by 57 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Ying Huang | Barclays |